Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.
van Wilpe S, Kloots ISH, Slootbeek PHJ, den Brok M, Westdorp H, Franken MD, Coskunturk M, Osinga T, Bloemendal H, Adema G, Smeenk RJ, Nagarajah J, van Ipenburg J, Kroeze LI, Ligtenberg MJL, Schalken J, Gerritsen WR, Mehra N. van Wilpe S, et al. Among authors: schalken j. Ann Oncol. 2024 Dec;35(12):1126-1137. doi: 10.1016/j.annonc.2024.09.004. Epub 2024 Sep 16. Ann Oncol. 2024. PMID: 39293514 Free article. Clinical Trial.
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
Slootbeek PHJ, Luna-Velez MV, Privé BM, van der Doelen MJ, Kloots ISH, Pamidimarri Naga S, Onstenk HE, Nagarajah J, Westdorp H, van Oort IM, Kroeze LI, Schalken JA, Bloemendal HJ, Mehra N. Slootbeek PHJ, et al. Among authors: schalken ja. Theranostics. 2024 Aug 1;14(12):4555-4569. doi: 10.7150/thno.96322. eCollection 2024. Theranostics. 2024. PMID: 39239510 Free PMC article.
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.
Weijers JAM, Verhaegh GW, Lassche G, van Engen-van Grunsven ACH, Driessen CML, van Erp NP, Jonker MA, Schalken JA, van Herpen CML. Weijers JAM, et al. Among authors: schalken ja. BMC Cancer. 2024 Sep 20;24(1):1174. doi: 10.1186/s12885-024-12889-0. BMC Cancer. 2024. PMID: 39304797 Free PMC article.
A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.
Srinivasan S, Kryza T, Bock N, Tse BWC, Sokolowski KA, Janaththani P, Fernando A, Moya L, Stephens C, Dong Y, Röhl J, Alinezhad S, Vela I, Perry-Keene JL, Buzacott K, Nica R; IMPACT Study; Gago-Dominguez M; PROFILE Study Steering Committee; Schleutker J, Maier C, Muir K, Tangen CM, Gronberg H, Pashayan N, Albanes D, Wolk A, Stanford JL, Berndt SI, Mucci LA, Koutros S, Cussenot O, Sorensen KD, Grindedal EM, Travis RC, Haiman CA, MacInnis RJ, Vega A, Wiklund F, Neal DE, Kogevinas M, Penney KL, Nordestgaard BG, Brenner H, John EM, Gamulin M, Claessens F, Melander O, Dahlin A, Stattin P, Hallmans G, Häggström C, Johansson R, Thysell E, Rönn AC, Li W, Brown N, Dimeski G, Shepherd B, Dadaev T, Brook MN, Spurdle AB, Stenman UH, Koistinen H, Kote-Jarai Z, Klein RJ, Lilja H, Ecker RC, Eeles R; Practical Consortium; Australian Prostate Cancer BioResource; Clements J, Batra J. Srinivasan S, et al. Nat Commun. 2024 Nov 6;15(1):9587. doi: 10.1038/s41467-024-52472-6. Nat Commun. 2024. PMID: 39505858 Free PMC article.
PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research.
Lawlor A, Beyer K, Russell B, Steinbeisser C, Bjartell A, De Meulder B, Omar MI, Hulsen T, Butler J, N'Dow J, Rivas JG, Gandaglia G, Nicoletti R, Sakalis V, Smith EJ, Maass M, Zong J, Fullwood L, Abbott T, Tafreshiha A, Papineni K, Snijder R, Horgan D, Seager S, Evans-Axelsson S, Ribal MJ, Roobol MJ, Van Hemelrijck M; PIONEER Consortium. Lawlor A, et al. Nat Rev Urol. 2024 Sep 9. doi: 10.1038/s41585-024-00925-4. Online ahead of print. Nat Rev Urol. 2024. PMID: 39251785 Review.
TTLL12 has a potential oncogenic activity, suppression of ligation of nitrotyrosine to the C-terminus of detyrosinated α-tubulin, that can be overcome by molecules identified by screening a compound library.
Deshpande A, Brants J, Wasylyk C, van Hooij O, Verhaegh GW, Maas P, Schalken JA, Wasylyk B. Deshpande A, et al. Among authors: schalken ja. PLoS One. 2024 Feb 23;19(2):e0296960. doi: 10.1371/journal.pone.0296960. eCollection 2024. PLoS One. 2024. PMID: 38394155 Free PMC article.
Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be?
Russell B, Beyer K, Lawlor A, Roobol MJ, Venderbos LDF, Remmers S, Briers E, MacLennan SJ, MacLennan S, Omar MI, Van Hemelrijck M; PIONEER Consortium. Russell B, et al. Eur Urol Open Sci. 2023 Dec 19;59:27-29. doi: 10.1016/j.euros.2023.11.004. eCollection 2024 Jan. Eur Urol Open Sci. 2023. PMID: 38298764 Free PMC article.
Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial.
Weijers JAM, de Bitter TJJ, Verhaegh GW, van Boxtel W, Uijen MJM, van Engen-van Grunsven ACH, Driessen CML, Schalken JA, Ligtenberg MJL, van Herpen CML. Weijers JAM, et al. Among authors: schalken ja. Oral Oncol. 2023 Dec;147:106620. doi: 10.1016/j.oraloncology.2023.106620. Epub 2023 Nov 6. Oral Oncol. 2023. PMID: 37939426 No abstract available.
451 results